Episode3: The Biologics Report Card

Episode 2 diagnosed the Generics Trap at the industry level and introduced the three-cluster stratification framework in general terms. Episode 3 applies that framework with full company-level specificity to the ten biologics subsidiaries of listed Indian pharma majors. This is the most data-dense episode in the series, closer to an equity research note delivered in audio form than a macro narrative.The deliverable for the listener is a working mental map. Ten names, three clusters, and a five-signal diagnostic they can apply themselves to any biologics subsidiary not covered here. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com